Melphalan-associated enteropathy in recipients of allogeneic hematopoietic stem cell transplantation: analysis of our own data and a literature review

S.B. Mukhammadiev; S.S. Asilov; K.A. Olimjonov; N.Kh. Kakharova; G.Z. Makhamadalieva; A.A. Kayumov; M.Yu. Drokov

Authors

S.B. Mukhammadiev Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan
S.S. Asilov Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan
K.A. Olimjonov Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan
N.Kh. Kakharova Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan
G.Z. Makhamadalieva Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan
A.A. Kayumov Republican Specialized Scientific and Practical Medical Center of Hematology of the Ministry of Health of the Republic of Uzbekistan
M.Yu. Drokov Federal State Budgetary Institution "National Medical Research Center of Hematology" of the Ministry of Health of Russia

Keywords:

melphalan-associated enteropathy, allogeneic HSCT, graft-versus, intestinal toxicity

Abstract

The widespread use of high-dose melphalan in conditioning regimens for allogeneic hematopoietic stem cell transplantation (allo-HSCT) has led to an increased incidence of melphalan-associated enteropathy (MAE), a severe toxic intestinal injury. A key challenge in management is its differentiation from acute graft-versus-host disease (GVHD)